NBT Bank N A NY lowered its holdings in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 1.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 28,980 shares of the financial services provider’s stock after selling 280 shares during the period. NBT Bank N A NY owned about 0.06% of iShares Biotechnology ETF worth $3,831,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also bought and sold shares of IBB. Concurrent Investment Advisors LLC boosted its position in iShares Biotechnology ETF by 3.4% during the third quarter. Concurrent Investment Advisors LLC now owns 3,712 shares of the financial services provider’s stock worth $541,000 after purchasing an additional 123 shares during the period. Graypoint LLC boosted its holdings in iShares Biotechnology ETF by 8.4% in the 3rd quarter. Graypoint LLC now owns 1,613 shares of the financial services provider’s stock worth $235,000 after buying an additional 125 shares during the period. Sigma Planning Corp boosted its holdings in iShares Biotechnology ETF by 11.7% in the 3rd quarter. Sigma Planning Corp now owns 7,083 shares of the financial services provider’s stock worth $1,031,000 after buying an additional 743 shares during the period. Tyler Stone Wealth Management grew its stake in iShares Biotechnology ETF by 128.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 5,747 shares of the financial services provider’s stock valued at $837,000 after buying an additional 3,226 shares in the last quarter. Finally, Ashton Thomas Securities LLC bought a new stake in iShares Biotechnology ETF during the 3rd quarter valued at $36,000. 62.45% of the stock is owned by institutional investors.
iShares Biotechnology ETF Price Performance
NASDAQ:IBB opened at $136.95 on Monday. The company has a market cap of $6.47 billion, a P/E ratio of 24.52 and a beta of 0.84. iShares Biotechnology ETF has a 1 year low of $123.60 and a 1 year high of $150.57. The stock’s fifty day moving average price is $136.08 and its two-hundred day moving average price is $140.22.
iShares Biotechnology ETF Cuts Dividend
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Further Reading
- Five stocks we like better than iShares Biotechnology ETF
- 3 Stocks to Consider Buying in October
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- Do ETFs Pay Dividends? What You Need to Know
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- How to Start Investing in Real Estate
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.